Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
83.09
-5.41 (-6.11%)
At close: Apr 28, 2026, 4:00 PM EDT
83.50
+0.41 (0.49%)
After-hours: Apr 28, 2026, 7:01 PM EDT
Guardant Health Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Guardant Health stock have an average target of 119.79, with a low estimate of 60 and a high estimate of 180. The average target predicts an increase of 44.17% from the current stock price of 83.09.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock from 19 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 7 | 7 | 7 |
| Buy | 15 | 13 | 12 | 12 | 12 | 11 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 21 | 21 | 20 | 20 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $130 → $115 | Buy | Maintains | $130 → $115 | +38.40% | Apr 14, 2026 |
| Evercore ISI Group | Evercore ISI Group | Hold Maintains $110 → $90 | Hold | Maintains | $110 → $90 | +8.32% | Apr 6, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $120 → $130 | Buy | Maintains | $120 → $130 | +56.46% | Feb 24, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $170 → $180 | Buy | Maintains | $170 → $180 | +116.63% | Feb 20, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $135 → $150 | Strong Buy | Maintains | $135 → $150 | +80.53% | Feb 20, 2026 |
Financial Forecast
Revenue This Year
1.31B
from 982.02M
Increased by 33.30%
Revenue Next Year
1.68B
from 1.31B
Increased by 28.27%
EPS This Year
-2.89
from -3.32
EPS Next Year
-1.97
from -2.89
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.4B | 1.9B | ||||||
| Avg | 1.3B | 1.7B | ||||||
| Low | 1.2B | 1.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 39.0% | 47.0% | ||||||
| Avg | 33.3% | 28.3% | ||||||
| Low | 25.9% | 16.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.27 | 0.38 | ||||||
| Avg | -2.89 | -1.97 | ||||||
| Low | -3.11 | -2.61 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.